reports
Xbrane Biopharma AB: 2 directors bought
Two Directors at Xbrane Biopharma AB bought 2,750 shares at between 76.200SEK and 78.400SEK. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
- Dr John Savin
Xbrane Biopharma - Mammalian movement
Xbrane, a leading innovative biosimilar development company, is moving into mammalian cell culture with announced plans for Xdivane, a biosimilar of the immunoncology blockbuster Opdivo (nivolumab, BMS). The company plans to launch Xdivane from 2026. Xbrane has issued guidance that its share of revenues from Xlucane, partnered with STADA and due for launch by Q122, could reach €100m. The XPLORE Phase III trial has enrolled its first patient, with its primary endpoint due in mid-2020. Our valua...
- Dr John Savin
Xbrane Biopharma - Biosimilar focus with Phase III trial about to star...
Xbrane now focuses on developing high-margin biosimilar products with Xlucane, its Lucentis biosimilar, as the lead product. After the July 2018 SEK78m upfront deal with STADA, Xbrane is starting the global XPLORE Phase III trial. The primary endpoint reports in mid-2020 and XPLORE completes in February 2021. Xbrane is raising SEK59.3m at SEK30/ share to help fund its 50% share of the XPLORE study. Xbrane sold SEK20m of Spherotide (a triptorelin generic) to Iran in 2018. A partner is needed to p...
Edison issues outlook on Xbrane Biopharma (XBRANE)
Edison Investment Research Limited Edison issues outlook on Xbrane Biopharma (XBRANE) 23-Nov-2018 / 13:37 GMT/BST London, UK, 23 November 2018 Edison issues outlook on Xbrane Biopharma (XBRANE) Xbrane (XBRANE:SS) now focuses on developing high-margin biosimilar products. In July, Xbrane did a deal with STADA on Xlucane, its Lucentis biosimilar and gained an upfront fee of EUR7.5m; management estimates that Xbrane's 50:50 profit share could be worth up to EUR100m per year. STADA will market Xlucane. Xbrane aims to start clinical development in Q119. In drug delivery, Spherotide bulk sales ...
- Dr John Savin
Xbrane Biopharma - Biosimilar focus after successful partnering
Xbrane now focuses on developing high-margin biosimilar products. In July, Xbrane did a deal with STADA on Xlucane, its Lucentis biosimilar and gained an upfront fee of €7.5m; management estimates that Xbrane’s 50:50 profit share could be worth up to €100m per year. STADA will market Xlucane. Xbrane aims to start clinical development in Q119. In drug delivery, Spherotide bulk sales to Iran were SEK14m to June 2018. In Europe, the key market, Spherotide development requires a partner to fun...
- Dr John Savin
Price-competitive generic and biosimilar therapies
Xbrane's first sales in 2017 will be of Spherotide: the first generic formulation of the prostate cancer therapy triptorelin (cancer sales about $380m). A SEK7m order is ready for shipment to Iran, once authorised. A Chinese deal worth SEK17m upfront, $8m total, may be signed in Q117. European partnering and launches are possible from 2019 after clinical trials. Xbrane (or a partner) may sell Xlucane, its low-cost biosimilar of Lucentis (2015 sales $3.6bn), in the US after 2021 and from 2022 in ...
- Dr John Savin
Price-competitive generic and biosimilar therapies
Xbrane's first sales in 2017 will be of Spherotide: the first generic formulation of the prostate cancer therapy triptorelin (cancer sales about $380m). A SEK7m order is ready for shipment to Iran, once authorised. A Chinese deal worth SEK17m upfront, $8m total, may be signed in Q117. European partnering and launches are possible from 2019 after clinical trials. Xbrane (or a partner) may sell Xlucane, its low-cost biosimilar of Lucentis (2015 sales $3.6bn), in the US after 2021 and from 2022 in ...
- Dr John Savin
Price-competitive generic and biosimilar therapies
Xbrane's first sales in 2017 will be of Spherotide: the first generic formulation of the prostate cancer therapy triptorelin (cancer sales about $380m). A SEK7m order is ready for shipment to Iran, once authorised. A Chinese deal worth SEK17m upfront, $8m total, may be signed in Q117. European partnering and launches are possible from 2019 after clinical trials. Xbrane (or a partner) may sell Xlucane, its low-cost biosimilar of Lucentis (2015 sales $3.6bn), in the US after 2021 and from 2022 in ...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.